Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03446157 · ClinicalTrials.gov registry record · Phase 2
Palbociclib and Cetuximab in Metastatic Colorectal Cancer
A Phase 2 study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT03446157 is a Phase 2 study that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 24 participants.
The verdict
NCT03446157, a Phase 2 study, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This research study is designed to provide a better understanding of study drugs cetuximab (Erbitux®) and palbociclib when used in combination to treat patients with metastatic colon cancer.
Interventions
- DRUG Cetuximab
- DRUG Palbociclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-03-23 |
| Est. Completion | 2026-01-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03446157
The ClinicalTrials.gov registry entry for NCT03446157 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cetuximab is the first listed.
NCT03446157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03446157 about?
NCT03446157 is a clinical study titled "Palbociclib and Cetuximab in Metastatic Colorectal Cancer". This research study is designed to provide a better understanding of study drugs cetuximab (Erbitux®) and palbociclib when used in combination to treat patients with metastatic colon cancer.
What is the current status of trial NCT03446157?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2018-03-23. Estimated completion is 2026-01-26.
What interventions are being tested in trial NCT03446157?
The interventions under investigation include: Cetuximab (DRUG), Palbociclib (DRUG).
Who is sponsoring clinical trial NCT03446157?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.